Henri Lichenstein

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark.

OrphAI Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in matching drugs to diseases and identifying the care for individual patients using Guardian Angel Artificial Intelligence algorithm. The company was founded by Tian Xu, Jonathan M. Rothberg and Henri S. Lichenstein in 2013 and is headquartered in Guilford, CT.

Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development.